HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

First clinical experience with anecortave acetate (Retaane).

AbstractBACKGROUND:
Anecortave acetate is an angiostatic cortisene which is injected as a posterior juxtascleral depot and has been shown to be effective in the treatment of exudative age-related macular degeneration (AMD). The compound is not yet approved in Switzerland but can be used as "compassionate use" in individual cases.
PATIENTS AND METHODS:
An uncontrolled case series with standardised documentation of ETDRS visual acuity, near acuity, need for magnification and fluorescein angiography was performed.
RESULTS:
22 eyes of 19 patients (8 male, 11 female, average age 78.8 years) were treated with a posterior juxtascleral depot injection (PJD) of 15 mg anecortave acetate. The mean change in visual acuity after 3 months in eyes treated with anecortave acetate was -2.6 ETDRS letters corresponding to 0.52 Snellen lines. 3/20 eyes gained more than 1 line. 11/20 eyes showed stable visual acuity (+/- 1 Snellen line, +/- 5 ETDRS letters). 5/20 eyes developed moderate vision loss (one to two Snellen lines, 6-10 ETDRS letters). 1/20 lost 18 ETDRS letters (> 3 Snellen lines). There were no moderate or severe adverse events.
CONCLUSIONS:
A PJD of 15 mg anecortave acetate is safe and well tolerated. In eyes with occult CNV without recent progression or with residual neovascular activity after photodynamic therapy anecortave acetate may be an alternative therapeutic option before considering intravitreal anti-VEGF agents due to the much less invasive character and lower risk profile.
AuthorsS Hayek, M Scherrer, D Barthelmes, J C Fleischhauer, M M Kurz-Levin, M Menghini, H Helbig, F K Sutter
JournalKlinische Monatsblatter fur Augenheilkunde (Klin Monbl Augenheilkd) Vol. 224 Issue 4 Pg. 279-81 (Apr 2007) ISSN: 0023-2165 [Print] Germany
PMID17458792 (Publication Type: Clinical Trial, Journal Article)
Chemical References
  • Angiogenesis Inhibitors
  • Pregnadienediols
  • anecortave acetate
Topics
  • Aged
  • Angiogenesis Inhibitors (administration & dosage)
  • Choroidal Neovascularization (complications, drug therapy)
  • Female
  • Humans
  • Injections
  • Macular Degeneration (complications, drug therapy)
  • Male
  • Pilot Projects
  • Pregnadienediols (administration & dosage)
  • Treatment Outcome
  • Vision Disorders (diagnosis, etiology, prevention & control)
  • Visual Acuity (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: